These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 19769734)
1. Dendritic cell-based vaccines for pancreatic cancer and melanoma. Mulé JJ Ann N Y Acad Sci; 2009 Sep; 1174():33-40. PubMed ID: 19769734 [TBL] [Abstract][Full Text] [Related]
2. Immune responses in the draining lymph nodes against cancer: implications for immunotherapy. Shu S; Cochran AJ; Huang RR; Morton DL; Maecker HT Cancer Metastasis Rev; 2006 Jun; 25(2):233-42. PubMed ID: 16770535 [TBL] [Abstract][Full Text] [Related]
3. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction. Okada N; Mori N; Koretomo R; Okada Y; Nakayama T; Yoshie O; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A Gene Ther; 2005 Jan; 12(2):129-39. PubMed ID: 15483669 [TBL] [Abstract][Full Text] [Related]
4. Antitumor immunity by a dendritic cell vaccine encoding secondary lymphoid chemokine and tumor lysate on murine prostate cancer. Lu J; Zhang Q; Liang CM; Xia SJ; Zhong CP; Wang DW Asian J Androl; 2008 Nov; 10(6):883-9. PubMed ID: 18958352 [TBL] [Abstract][Full Text] [Related]
6. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. den Brok MH; Sutmuller RP; Nierkens S; Bennink EJ; Toonen LW; Figdor CG; Ruers TJ; Adema GJ Cancer Res; 2006 Jul; 66(14):7285-92. PubMed ID: 16849578 [TBL] [Abstract][Full Text] [Related]
7. Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma. Gordon LK; Ribas A; Nusinowitz S; Butterfield LH; Glaspy JA; Economou JS; Straatsma BR Control Clin Trials; 2004 Aug; 25(4):400-7. PubMed ID: 15296814 [TBL] [Abstract][Full Text] [Related]
8. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Verdijk P; Aarntzen EH; Lesterhuis WJ; Boullart AC; Kok E; van Rossum MM; Strijk S; Eijckeler F; Bonenkamp JJ; Jacobs JF; Blokx W; Vankrieken JH; Joosten I; Boerman OC; Oyen WJ; Adema G; Punt CJ; Figdor CG; de Vries IJ Clin Cancer Res; 2009 Apr; 15(7):2531-40. PubMed ID: 19318472 [TBL] [Abstract][Full Text] [Related]
9. Dendritic cell vaccines in melanoma: from promise to proof? Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431 [TBL] [Abstract][Full Text] [Related]
10. Optimizing dendritic cell-based immunotherapy for cancer. Zhong H; Shurin MR; Han B Expert Rev Vaccines; 2007 Jun; 6(3):333-45. PubMed ID: 17542749 [TBL] [Abstract][Full Text] [Related]
13. Conditioning vaccination site with irradiated MIP-3alpha-transfected tumor cells enhances efficacy of dendritic cell-based cancer vaccine. Shih NY; Yang HY; Cheng HT; Hung YM; Yao YC; Zhu YH; Wu YC; Liu KJ J Immunother; 2009 May; 32(4):363-9. PubMed ID: 19342969 [TBL] [Abstract][Full Text] [Related]
14. Modification of dendritic cells with interferon-gamma-inducible protein-10 gene to enhance vaccine potency. Kang TH; Bae HC; Kim SH; Seo SH; Son SW; Choi EY; Seong SY; Kim TW J Gene Med; 2009 Oct; 11(10):889-98. PubMed ID: 19618483 [TBL] [Abstract][Full Text] [Related]
15. DC-based cancer vaccines. Gilboa E J Clin Invest; 2007 May; 117(5):1195-203. PubMed ID: 17476349 [TBL] [Abstract][Full Text] [Related]
16. More than chemotaxis: a new anti-tumor DC vaccine modified by rAAV2-SLC. Liang CM; Ye SL; Zhong CP; Zheng N; Bian W; Sun RX; Chen J; Li RL; Zhou S; Liu YK Mol Immunol; 2007 Jul; 44(15):3797-804. PubMed ID: 17521735 [TBL] [Abstract][Full Text] [Related]
17. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model. Berinstein NL Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743 [TBL] [Abstract][Full Text] [Related]
18. Chemokines and anti-cancer immunotherapy: anti-tumor effect of EBI1-ligand chemokine (ELC) and secondary lymphoid tissue chemokine (SLC). Nomura T; Hasegawa H Anticancer Res; 2000; 20(6A):4073-80. PubMed ID: 11131675 [TBL] [Abstract][Full Text] [Related]
19. [A possibility of overcoming local tumor immune tolerance by radiofrequency ablation in combination with intratumoral injection of naïve dendritic cell]. Saji H; Song W; Nakamura H; Saijo T; Hosaka M; Hagiwara M; Ogata A; Kawasaki N; Engleman EG; Kato H Gan To Kagaku Ryoho; 2006 Nov; 33(12):1736-8. PubMed ID: 17212091 [TBL] [Abstract][Full Text] [Related]
20. A novel approach to improve immune effector responses post transplant by restoration of CCL21 expression. Stefanski HE; Jonart L; Goren E; Mulé JJ; Blazar BR PLoS One; 2018; 13(4):e0193461. PubMed ID: 29617362 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]